Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the ...
In 2025, IonQ IONQ and Rigetti Computing RGTI gained the attention of investors tracking the rapid evolution of the quantum computing sector. Throughout the year, IonQ demonstrated accelerating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback